Treatment prediction by subset analysis of tumor infiltrating lymphocytes (TILs) in combination therapy with trastuzumab, pertuzumab, and docetaxel for advanced HER2-positive breast cancer

被引：0
|
作者：
Takada, Koji [1 ]
Kashiwagi, Shinichiro [1 ]
Asano, Yuka [1 ]
Wataru, Goto [1 ]
Morisaki, Tamami [1 ]
Noda, Satoru [1 ]
Takashima, Tsutomu [1 ]
Onoda, Naoyoshi [1 ]
Hirakawa, Kosei [1 ]
Ohira, Masaichi [1 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Osaka, Japan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3119
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Predictive role of stromal tumor infiltrating lymphocytes (TILs) in patients with metastatic HER2-positive breast cancer (BC) treated with trastuzumab
    Yoon, J. A.
    Yoo, C.
    Lee, H. J.
    Kim, K-P
    Kim, J.
    Ahn, J-H
    Jung, K. H.
    Gong, G.
    Kim, S-B
    CANCER RESEARCH, 2016, 76
  • [22] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
    Xu, Dongdong
    Wu, Jiang
    Yu, Jing
    Yang, Yuqing
    Wen, Xinxin
    Yang, Jixin
    Wei, Hongliang
    Xu, Xiaolong
    Li, Yike
    Yang, Liu
    Wang, Lei
    Wang, Yijia
    Ma, Wen
    Li, Nanlin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
    Tian, Tian
    Ye, Jing
    Zhou, Sihai
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 720 - 727
  • [24] ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL
    Ribeiro, I
    Lourenco, O.
    Alves, C.
    Thuresson, P.
    Monteiroa, I
    Batel-Marques, F.
    VALUE IN HEALTH, 2016, 19 (07) : A736 - A737
  • [25] Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report
    Yamashita, Yuji
    Tanaka, Yuko
    Kono, Seishi
    Nishimura, Meiko
    Mukohara, Toru
    Morinaga, Yukiko
    Hara, Shigeo
    Takao, Shintaro
    BREAST CARE, 2017, 12 (01) : 45 - 47
  • [26] Distichiasis in association with entropion in metastatic HER2-positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy
    Tas, Faruk
    Ozturker, Can
    BREAST JOURNAL, 2020, 26 (05): : 1004 - 1006
  • [27] Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer
    Luen, Stephen J.
    Loi, Sherene
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (01)
  • [28] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [29] A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
    Yamashita, Yuji
    Tanaka, Yuko
    Nishimura, Meiko
    Mukohara, Toru
    Kono, Seishi
    Takao, Shintaro
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [30] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
12345